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Hematopoietic stem cells (HSCs) emerge during
embryogenesis from hemogenic endothelium, but it
remains unclear how the HSC lineage is initially
established from mesoderm during ontogeny. In
Xenopus, the definitive hemangioblast precursors
of the HSC lineage have been identified in dorsal
lateral plate (DLP) mesoderm, and a transcriptional
gene regulatory network (GRN) controlling heman-
gioblast programming has been elucidated. Herein,
we identify an essential role for microRNAs (miRNAs)
in establishing the mesodermal lineage leading to
both HSC emergence and vasculogenesis and deter-
mine that a single miRNA, miR-142-3p, is primarily
responsible for initiation of definitive hemangioblast
specification. miR-142-3p forms a double-negative
gate unlocking entry into the hemangioblast pro-
gram, in part by inhibiting TGFb signaling. Our results
table miR-142-3p as a master regulator of HSC line-
age specification, sitting at the apex of the hierarchy
programming the adult hemangioblast, thus illus-
trating that miRNAs can act as instructive determi-
nants of cell fate during development.
INTRODUCTION
Hematopoietic stem cells (HSCs) are formed during embryogen-
esis and are required to maintain the hematopoietic system
throughout life (Medvinsky and Dzierzak, 1996). Understanding
how HSCs are programmed will inform protocols for ex vivo
production and expansion of HSCs for regenerative medicine.
The emergence of HSCs occurs through an endothelial to
hematopoietic transition (EHT) of hemogenic endothelial cells lin-
ing the dorsal aorta (DA) in the aorta-gonad-mesonephros (AGM)
region (Bertrand et al., 2010; Boisset et al., 2010; Kissa and Her-
bomel, 2010). However, the origin of the hemogenic endothelium
and the mechanism by which the HSC lineage is first established
is less well understood (Medvinsky et al., 2011). Current proto-Developcols for ex vivo hematopoietic differentiation of mammalian
pluripotent cells are able to mimic an EHT but are incapable of
producing definitive, long-term reconstituting HSCs (McKinney-
Freeman andDaley, 2007). It is therefore important to understand
how the precursors of the HSC lineage, the definitive hemangio-
blasts, are programmed during embryonic development in order
to achieve the production of functional HSCs in vitro.
Lineage tracing in the mouse has suggested that both hemo-
genic and vascular endothelial cells in the DA originate from the
lateral plate mesoderm (Wasteson et al., 2008; Zovein et al.,
2010), and in Xenopus, in marked contrast to the mouse, this
definitive hemangioblast population has been prospectively
identified (Ciau-Uitz et al., 2000; Walmsley et al., 2002). The
dorsal lateral plate (DLP) mesoderm contains hemangioblasts
that coexpress blood and endothelial genes and give rise to
both endothelial cells of the major vessels as well as the hemo-
genic endothelium in the ventral wall of the DA, from which
HSCs emerge (summarized in Figure 1A). The hemangioblasts
in the DLP migrate to the midline in response to VEGF signaling,
coalesce, and lumenise to form the DA, whereas some remain in
the lateral plate and produce the posterior cardinal veins (PCV)
(Ciau-Uitz et al., 2000; Cleaver and Krieg, 1998). Transplantation
experiments showed that the DLP region, but not the ventral
blood island (VBI), gives rise to adult blood, demonstrating that
this tissue contains the precursors of the adult blood stem cell
lineage (Mae´no et al., 1985).
Genetic analysis in Xenopus has begun to define a transcrip-
tional road map for programming the blood stem cell lineage
from definitive hemangioblasts through to HSCs (Ciau-Uitz
et al., 2010, 2013; Liu et al., 2008; Walmsley et al., 2002). The
Ets transcription factor (TF) Fli1, sits at the top of this hierarchy
and promotes expression of a cascade of TFs and signaling mol-
ecules, including Gata2, Flk1, and Etv2, that collaborate to
activate the key hemangioblast determinant, Scl, which then
activates a battery of downstream effector genes in order to pro-
duce both hemogenic and vascular endothelium (Ciau-Uitz et al.,
2013). BMP and VEGF signaling have been found to promote the
specification of this hemangioblast population during embryo-
genesis, but it is not known how this genetic cascade is initiated
(Ciau-Uitz et al., 2010, 2013;Walmsley et al., 2002). Interestingly,
many of the same TFs that regulate adult HSC function are
required for HSC development in the embryo and recent studiesmental Cell 26, 237–249, August 12, 2013 ª2013 Elsevier Inc. 237
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transcriptional connections between these TFs and their target
genes using chromatin immunoprecipitation sequencing (ChIP-
seq) analysis (Pimanda and Go¨ttgens, 2010; Wilson et al.,
2010; G. May, S.S., and T.E., unpublished data). Ultimately,
these gene regulatory networks (GRNs) will provide important
clues for recapitulating embryonic development in vitro in order
to produce functional, long-term reconstituting HSCs from
pluripotent stem cells for regenerative medicine.
We set out to investigate howmicroRNAs (miRNAs) contribute
to the emergence of the blood stem cell lineage during embry-
onic development. miRNAs are a new class of gene regulatory
molecules that act at the posttranscriptional level to repressmul-
tiple target genes via inhibition of translation and destabilization
of mRNA (reviewed in Nimmo and Slack, 2009). miRNA function
has been studied by globally ablating miRNA production by
knocking out genes required for miRNA processing, such as
Dicer, Drosha, and Dgcr8. These studies have shown that
miRNAs are fundamentally required for embryogenesis in mice
(Bernstein et al., 2003; Chong et al., 2010; Murchison et al.,
2005;Wang et al., 2007), and evidence abounds formiRNA regu-
lation of adult hematopoiesis (Alemdehy and Erkeland, 2012;
Baltimore et al., 2008). Conditional Dicer knockout in adult
bone marrow using the Mx-Cre system results in a catastrophic
loss of HSCs, illustrating that miRNAs have a major role in adult
HSC homeostasis (Guo et al., 2010). It is not yet known which
miRNAs are responsible for this defect, and furthermore, the
contribution that miRNAs make to the development of HSCs
and their hematoendothelial precursors during embryogenesis
has yet to be investigated.
By knocking down the miRNA-processing factor, Dgcr8, in
Xenopus embryos, we have discovered a role for miRNAs in early
specification of the HSC lineage in lateral plate mesoderm. The
failure to correctly specify hemangioblasts in the DLP results in
defects in vasculogenesis and disruption of DA formation, result-
ing in a complete ablation of HSC emergence. Using loss- and
gain-of-function approaches, we identify a single hematopoietic
miRNA, miR-142-3p, that is both necessary for specification of
definitive hemangioblasts and sufficient to rescue hemangio-Figure 1. Identification of a Role for miRNAs in Specification of the HS
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Developblast programming in embryos globally depleted of miRNAs by
Dgcr8 knockdown. Genetic analysis positions this miRNA at
the top of the regulatory hierarchy controlling hematoendothelial
programming in the DLP, acting in part via modulation of TGFb
signaling.
RESULTS
Identification of a miRNA Required for Definitive
Hemangioblast Specification
We first asked whether miRNAs are required for HSC formation
by inhibiting miRNA processing. miRNAs are produced by the
action of two main processing complexes: the Microprocessor
complex components Drosha and Dgcr8 excise the pre-miRNA
hairpin from the primary transcripts, and the terminal loop is then
removed by Dicer to release the mature miRNA duplex, one
strand of which is loaded into the silencing complex RISC (Kim
et al., 2009). We depleted Xenopus embryos of miRNAs using
a dgcr8 translation blocking morpholino (MO) (Agrawal et al.,
2009) to assess on a global scale whether miRNAs are required
for HSC formation. To minimize nonspecific effects and to opti-
mize viability, the MO dosage was titrated to an optimal range
of 10–15 ng per embryo. Using runx1 as a marker, we observed
a complete ablation of hemogenic endothelium in the dgcr8mor-
phants even at the lowest (10 ng) dose, at which the overall
morphology and survival of the embryos was good (Figure 1B).
Interestingly, earlier in development at stages 22–26, the number
of Flk1+ definitive hemangioblasts in the DLP was severely
reduced in dgcr8 morphants, suggesting that the failure to pro-
duce HSCs is caused by defective specification of hemangio-
blast precursors in lateral platemesoderm (Figure 1B; Figure S1A
available online).
Having established that miRNA production is crucial for the
specification of the hemangioblast precursors of HSCs, we
then asked which miRNA, or miRNAs, are responsible. Candi-
date miRNAs associated with the development of the definitive
hematopoietic lineage were identified by miRNA expres-
sion profiling of embryonic HSC precursors. The mouse sys-
tem affords the ability to prospectively isolate hematopoieticC Lineage
ll lineage in Xenopus, from DLP hemangioblast precusors through to HSCs via
he hemogenic endothelium in the ventral wall from which stem cells emerge as
44 of the Xenopus embryo are analogous to the clusters found in the E11.5 AGM
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ilable in Table S1. See Figure S1D for gating strategy of the sort and Figure S1E
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during the transit of HSC precursors from hemogenic endothe-
lium to HSCs (Ruiz-Herguido et al., 2012; Rybtsov et al., 2011;
Yokomizo and Dzierzak, 2010). We fluorescence-activated cell
sorting (FACS) isolated E11.5 AGM-derived populations contain-
ing hematopoietic stem and progenitors (HSPCs: Ter119
CD31+ c-Kit+ CD45+), the immature pre-HSCs (pre-HSC:
Ter119 CD31+ c-Kit+ CD45), and endothelial cells (including
hemogenic endothelium) (E: Ter119 CD31+ c-Kit CD45) (Fig-
ures S1D and S1E). These AGM populations represent a later
stage in HSC development than the hemangioblast and are
instead equivalent to the cells found in the hematopoietic clus-
ters in the dorsal aorta in stage 43 Xenopus embryos. A global
comparison of miRNA expression was performed using TaqMan
Rodent MicroRNA Arrays (frommiRbase [v. 10.1]) (Table S1). We
hypothesized that miRNAs involved in HSC lineage specification
would be expressed at all stages of HSC development from
hemogenic endothelium through to pre-HSC and HSPCs and
would be upregulated as the cells progressed to the hematopoi-
etic fate. Based on these criteria, we used hierarchical clustering
to identify a group of HSPC-associated miRNAs, termed
‘‘HSPC-miRs’’ (Figure 1C; Table S1).
Recently, it was shown that combinatorial binding of key
hematopoietic TFs is enriched at genes expressed in hematopoi-
etic progenitor cells and is a useful tool to predict novel HSPC
regulators (Hannah et al., 2011; Wilson et al., 2010). Therefore,
we ranked this cluster of ‘‘HSPC-miRs’’ based on the number
of binding peaks within 5 kb of the pre-miRNA locus for tenmajor
hematopoietic TFs (Scl, Lyl1, Lmo2, Runx1, Gata2, Meis1, Erg,
Fli1, Pu.1, and Gfi1b) using existing ChIP-seq data obtained in
multipotential hematopoietic progenitor cells (Wilson et al.,
2010) and identified miR-142-3p as the top-ranked hematopoi-
etic miRNA in this analysis (Figure 1D). All three of the AGM
populations analyzed expressed miR-142-3p, but it is strongly
upregulated in the HSPC population (Figure 1E). High-level
expression is maintained in adult bone-marrow-derived HSPCs
(Flt3KLS) (Figure 1E), consistent with the prior observations
that miR-142-3p is abundant specifically in hematopoietic cells
(Bissels et al., 2011; Chen et al., 2004). miR-142-3p is absolutely
conserved across vertebrates and has been previously reported
to modulate the maturation of the myeloid, erythroid, and T cell
lineages (Chen et al., 2004; Nishiyama et al., 2012; Wang et al.,
2012b), but its role in the ontogeny of HSCs has not been inves-
tigated. miR-142-3p is likely to be the major functional form of
this miRNA in HSC development as the opposite strand of
miR-142, miR-142-5p, is virtually undetectable in endothelium
and pre-HSCs and is expressed at a much lower level than
miR-142-3p in embryonic HSPCs (almost 1,000-fold lower
expression, Figure 1E).
We next asked whether this miRNA is also expressed in
the precursors to the hemogenic endothelium in lateral plate
mesoderm, because the HSC defect in our dgcr8 morphants
originated in an earlier failure to specify this hemangioblast
population. The profiling of AGM hematopoietic and endothelial
populations identified miRNAs expressed proximal to HSC
emergence, but their hemangioblastic anlage could not be
analyzed in murine embryos as this population has not yet
been prospectively isolated. However, in Xenopus, definitive
hemangioblasts have been shown to be located in the DLP of240 Developmental Cell 26, 237–249, August 12, 2013 ª2013 Elsevietailbud stage embryos (Ciau-Uitz et al., 2000; Walmsley et al.,
2002) (shown schematically in Figure 1A). qRT-PCR analysis
on DLP tissue dissected from stage 26 embryos revealed that
both strands of miR-142 are expressed in the definitive heman-
gioblast population with miR-142-3p present at a much higher
level than miR-142-5p, similar to our observations in the mouse
AGM (Figure 1F). Therefore, miR-142-3p is expressed in all
stages of the HSC lineage during development, including defin-
itive hemangioblasts, and themiR-142 locus is subject to combi-
natorial binding bymultiple major hematopoietic TFs, tabling this
miRNA as a candidate effector of hematopoietic programming
during development.
To directly test the hypothesis that this miRNA is responsible
for specification of the precursors of the blood stem cell lineage,
we carried out a combination of genetic approaches in Xenopus
embryos (summarized in Figure 2). Initially, we performed a miR-
142-3p loss-of-function (LOF) experiment using an antisense
MO to inhibit miR-142-3p activity (Figure 2). miR-142-3p mor-
phants failed to form hemogenic endothelium as judged by a
complete loss of runx1 expression in the midline of stage 39
embryos (Figure 3A), thus phenocopying the hematopoietic
defect seen in dgcr8 morphants. In contrast, a negative control
MO, with six mismatches compared to the miR-142-3p MO,
had no effect on the expression of runx1 (Figure 3B). Similar to
dgcr8 morphants, the HSC defect associated with miR-142-3p
MO could be traced back to the failure to correctly specify
hemangioblasts as the morphants had highly reduced flk1
expression in the DLP at stage 26, with a complete ablation of
flk1 staining in the posterior region of the DLP (Figure 3A). In
contrast, neither the control mismatch MO nor a MO targeting
the less abundant strand, miR-142-5p, had any effect on flk1
expression in the DLP (Figures 3B and 3C). The miR-142-3p
MO therefore phenocopies the effect of the dgcr8 MO on defin-
itive hemangioblast specification, strongly suggesting that
depletion of miR-142-3p is responsible for the failure to activate
the hematoendothelial program in the DLP of dgcr8 morphants.
miR-142-3p Is Sufficient to Rescue Definitive
Hemangioblast Specification in Dgcr8 Morphants
To test the hypothesis that depletion of miR-142-3p is respon-
sible for the definitive hemangioblast specification defect in
dgcr8morphants, we performed a rescue experiment with a syn-
thetic miR-142-3p mimic that does not require prior processing
by the Drosha/Dgcr8 complex and is instead optimized for direct
loading into RISC (summarized in Figure 2). Coinjection of 10 or
12.5 fmol mimic with dgcr8 MO was sufficient to restore
hemangioblast specification in dgcr8 morphants as assessed
by expression of flk1 and scl in the DLP at stage 26 (Figure 3D).
We also tested the other top candidates from our miRNA
screening, miR-26, miR-24, and miR-191, as well as the minor
strand of miR-142, miR-142-5p, for their ability to rescue dgcr8
morphants, but none of these were able to restore flk1 expres-
sion in the DLP (Figure S2A). Interestingly, themiR-142-3pmimic
was unable to restore formation of hemogenic endothelium from
these hemangioblasts (Figures S2B and S2C), suggesting that
other miRNAs are required for later stages of hemangioblast
differentiation. Taken together, these data strongly support the
hypothesis that miR-142-3p is the primary miRNA governing
definitive hemangioblast specification in lateral plate mesoderm.r Inc.
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Figure 2. A Combination of Genetic Approaches to Investigate miRNA Function in Xenopus Embryos
Schematic diagram summarizing the different approaches used to show that miR-142-3p is necessary and sufficient for hemangioblast specification during
establishment of the HSC lineage. A combination of loss-of-function (LOF), gain-of-function (GOF), and rescue experiments were used to investigate whether
miR-142-3p controls definitive hemangioblast specification.
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investigate whether overexpression of miR-142-3p is sufficient
to enhance hemangioblast and HSC specification (summarized
in Figure 2). Hemogenic endothelium is normally restricted to
the trunk region of the DA, but in the embryos injected with
miR-142-3p mimic, expression of runx1 is also found ectopically
in the tail region at stage 39 (indicated with red dashed line in Fig-
ure 3E), suggesting that miR-142-3p overexpression enhances
HSC programming in the DA. In addition, there is a mild posterior
expansion of gfi1a expression within the trunk DA of these
embryos (Figure S2D), although it is not expressed in the tail
region, suggesting that these ectopic runx1-expressing cells
may not be fully programmed HSC precursors. Earlier, at stage
26, some enhancement of flk1 staining in the DLP was also
observed (Figure 3E). Therefore, miR-142-3p enhances hemato-
poietic programming in the DLP and DA but may not be sufficient
by itself to drive ectopic HSC formation. Taken together, the
rescue and overexpression experiments endorse the view that
miR-142-3p is a central player in the development of the heman-
gioblast precursors of the blood stem cell lineage in lateral plate
mesoderm.
miR-142-3p Acts at the Top of the Regulatory
Hierarchy Specifying the Blood and Endothelial
Program in the DLP
The specification of the hemangioblastic precursors of definitive
HSCs and endothelium is dependent upon a hierarchicalDevelopnetwork of transcription factors and signaling molecules (Ciau-
Uitz et al., 2010; 2013; Liu et al., 2008; Walmsley et al., 2002;
summarized in Figure 4A). To investigate where miR-142-3p is
positioned in this regulatory hierarchy, we analyzed expression
of the known members of the network in the miR-142-3p mor-
phants (Figures 4B and 4C). The DLP network has an initiation
phase from stages 20–22, in which Fli1 and Gata2 switch on
flk1 and etv2 expression, followed by a lockdown/maintenance
phase from stage 22 onward driven by Etv2 acting in a positive
feedback loop to maintain gata2 expression (Figure 4A; Ciau-
Uitz et al., 2010, 2013; Liu et al., 2008). All of these TFs then
collaborate with VegfA-Flk1 signaling to activate scl expression
from stage 24, and Scl then activates a battery of downstream
hemangiogenic genes involved in endothelial and hematopoietic
differentiation (Ciau-Uitz et al., 2010, 2013). Recent work has un-
equivocally positioned Fli1 at the apex of the hierarchy regulating
hemangioblast specification in Xenopus. A detailed time course
analysis of gene expression showed that other factors, including
gata2, etv2, flk1, and scl, are all downregulated in the DLP of Fli1
morphants, whereas fli1 expression is unaffected by knockdown
of these downstream factors (Ciau-Uitz et al., 2013).
Early in hemangioblast development at stage 22, during estab-
lishment of the hemangioblast program, there is a severe reduc-
tion in the expression of the most upstream regulators, fli1, flk1,
and etv2, in the miR-142-3p morphants (Figure 4B). The full
hemangioblast program is normally activated by stages 25–26.
However, in miR-142-3p morphants, we discovered that all ofmental Cell 26, 237–249, August 12, 2013 ª2013 Elsevier Inc. 241
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Figure 3. miR-142-3p Is Required for Definitive Hemangioblast Specification and Is Sufficient to Rescue Hemangioblast Programming in
dgcr8 Morphants
(A–C) LOF experiment: miR-142-3p is required for formation of hemogenic endothelium and for hemangioblast specification in the DLP. Embryos injected with
100 ngmiR-142-3pMO (A), but not amismatch control MO (B), phenocopy hematopoietic defects of Dgcr8MOembryos. Top:WISH showing runx1 expression in
hemogenic endothelium (arrowheads) at stage 39. Bottom:WISH showing flk1 expression in DLP hemangioblasts (red arrows) at stage 24. Endothelial cells in VBI
are indicated by black arrows. (C) WISH showing flk1 expression is normal in the DLP (arrows) at stage 24 in miR-142-5p (passenger strand) morphants.
(D) Rescue experiment: Coinjection of the miR-142-3p mimic is sufficient to restore hemangioblast formation in dgcr8morphants. Expression of flk1 (top) and scl
(bottom) in the DLP (arrows) analyzed by WISH at stages 24–25.
(E) GOF experiment: Enhanced hematopoietic programming by overexpression of miR-142-3p. Left: WISH of runx1 at stage 39 shows that the hemogenic
endothelium (arrowheads) is expanded posteriorly out of the trunk, into the postcloacal tail region of the DA (arrows) in the miR-142-3p mimic-injected embryos.
Dashed line indicates the location of the cloaca. Right: WISH analysis of flk1 expression in the DLP hemangioblasts (arrows) at stages 24–25.
The number of embryos represented by each panel, out of the number analyzed, is indicated in the top right corner. The anterior of the embryo is to the left and
dorsal to the top in all images.
See also Figure S2.
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miR-142 Controls Hemangioblast Specificationthe major TFs and signaling molecules acting in this genetic
cascade (fli1, gata2, flk1, etv2, and scl) are severely downregu-
lated in the DLP (Figure 3A [flk1]; Figure 4C). In contrast, heman-
gioblast programming is normal in embryos injected with either
the control mismatch MO or the miR-142-5p (passenger strand)
MO (Figures 3B, 3C, 4D, and 4E). Therefore, miR-142-3p is
required for initiation of both the VEGF-dependent and VEGF-in-
dependent branches of the hemangioblast program and acts
above Fli1, at the apex of the regulatory hierarchy governing242 Developmental Cell 26, 237–249, August 12, 2013 ª2013 Elsevieinitiation of the definitive hemangioblast program in the DLP
mesoderm.
Furthermore, dgcr8 morphants have similar defects in DLP
hemangioblast specification as shown by reduced expression
of fli1 and flk1 at stage 22 (Figure S1A) and flk1, etv2, and scl
at stages 25–26 (Figures 1B, 3D, and S1A). The striking pheno-
copy of the dgcr8 and miR-142-3p morphant phenotypes in
the DLP, and the ability of the miR-142-3p mimic to rescue
hemangioblast programming in dgcr8 morphants, stronglyr Inc.
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Figure 4. miR-142-3p Acts at the Top of theRegulatory Hierarchy Controlling Specification of HSC and Endothelial Cell Precursors in theDLP
(A) A provisional GRN controlling hemangioblast specification (Ciau-Uitz et al., 2010, 2013; Liu et al., 2008; Walmsley et al., 2002).
(B and C) Initiation of the hemangioblast program is defective in miR-142-3p MO embryos. (B) WISH showing that expression of early regulators, fli1, flk1, and
etv2, is already highly reduced or absent in the DLP (arrows) in miR-142-3p morphants at stage 22 (initiation phase). (C) WISH analysis showing that the
expression of hematopoietic gata2 and scl) and endothelial (fli1 and etv2) TFs in the DLP (arrows), are all dependent onmiR-142-3p at stages 25–26. Boxed region
of the fli1 panels is magnified to show that the expression of fli1 in the pronephric duct (arrowheads) abutting the DLP is unaffected in the morpants, whereas the
expression of fli1 in the DLP (white dashed outline and arrows) is abrogated by the miR-142-3p MO. Formation of endothelial cells in the VBI is also disrupted by
the MO as shown by reduced etv2 staining (arrowhead).
(D and E) Hemangioblast specification is normal in embryos injected with the control mismatch MO andmiR-142-5p MO showing that the effect is specific to the
miR-142-3p MO. (D) WISH analysis of etv2 and scl expression in the DLP (arrows) of control mismatch morphants and (E) gata2 and etv2 expression in the DLP
(arrows) of miR-142-5p morphants.
(F) Formation of primitive blood is defective in miR-142-3p morphants. Top: Erythroid differentiation is absent from the pVBI region as shown byWISH analysis of
aT4-globin expression. Bottom: reduction in formation of myeloid cells as shown by WISH analysis of elas1 expression.
The number of embryos represented by each panel, out of the number analyzed, is indicated in the top right corner. The anterior of the embryo is to the left and
dorsal to the top in all images.
See also Figure S3.
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miR-142 Controls Hemangioblast Specificationsupports the view that miR-142-3p is the major miRNA acting to
initiate hematoendothelial fate in the DLP.
In addition, the formation of embryonic blood and the vitelline
vessels in the VBI is also disrupted in miR-142-3p morphants.DevelopThe VBI is lineally, spatially, and temporally separated from
the definitive hematoendothelial lineage derived from the DLP
(Ciau-Uitz et al., 2000). The ability to analyze the early specifi-
cation of the two waves of hematopoiesis separately is anmental Cell 26, 237–249, August 12, 2013 ª2013 Elsevier Inc. 243
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revealed that miR-142-3p is required for the differentiation of
myeloid cells from the anterior VBI and erythroid cells in the pos-
terior VBI, suggesting that it plays a role in establishing both
primitive and definitive waves of hematopoiesis (Figure 4F). In
addition, the number of endothelial cells arising from the VBI is
severely reduced in the miR-142-3p morphants (Figure 3A
[flk1], black arrow; Figure 4C [etv2], red arrowhead). In agree-
ment with these observations, dgcr8 morphants exhibit similar
defects in hematopoiesis and vasculogenesis in the VBI (Figures
S1A and S1C). The defect in erythroid differentiation is consis-
tent with the recent observations of Nishiyama and colleagues
that zebrafish embryos depleted of miR-142-3p have reduced
numbers of primitive erythrocytes (Nishiyama et al., 2012).
The specificity of miR-142-3p in promoting hemangioblast
development is demonstrated by the observation that the pro-
nephric duct, which derives from the same C3 blastomere of
32-cell stage embryos as the DLP (Ciau-Uitz et al., 2000) and
develops directly adjacent to the DLP, is nonetheless specified
normally (Figure S3A). It has also been recently suggested that
in zebrafish, miR-142-3p depletion causes defects in cardiac
function and somite morphogenesis later in development (Nish-
iyama et al., 2012). However, at the stages when the DLP meso-
derm is being specified to a hematoendothelial fate, both cardiac
tissue and somites are specified normally (Figures S3B and
S3C). Therefore, miR-142-3p specifically promotes hemangio-
blast specification in lateral plate mesoderm and does not
appear to have a more widespread role in mesoderm induction
or patterning.
miR-142-3p Morphants Have Defective Vasculogenesis
Arising from the Failure to Specify Definitive
Hemangioblasts
The definitive hemangioblasts in the DLP are responsible for pro-
duction of vascular endothelial cells of the DA and PCV, as well
as hemogenic endothelium in the DA (summarized in Figure 1A).
Hemogenic endothelium is not formed inmiR-142-3pmorphants
as shown by complete ablation of the hematopoietic genes
runx1, spib, and gfi1a in the trunk region of the DA (Figures 1B
and 5A). We therefore also examined the expression of various
endothelial markers in the miR-142-3p and dgcr8 morphants.
At stage 30, when hemangioblast-derived cells would normally
be undergoing VEGFA-dependent migration to the midline to
form the DA, effector genes downstream of Scl, including the
VEGF receptors flt1 and flt4, are downregulated in the miR-
142-3p morphants, and there are reduced numbers of endothe-
lial precursors migrating to the midline (Figure 5B). By stage 34
severe defects are seen in the formation of both the DA and
the PCV as assessed byCD31 andAA4.1 expression (Figure 5C),
and there are fewer cells expressing the arterial markers dll4 and
cx37 in the midline of the morphants (Figure 5C). A disorganized
vascular plexus is formed in the morphants, albeit a much
reduced abnormal vascular network with no fully intact DA (Fig-
ures 5C and 5D). The dgcr8 morphants have similar defects in
vasculogenesis as shown by AA4.1 and CD31 expression (Fig-
ure S1B). In contrast, the control mismatch MO had no effect
on endothelial cell differentiation (Figures S4A and S4B).
There is no circulation apparent in the miR-142-3p or dgcr8
morphants at stage 39 as a result of the severe vascular defects.244 Developmental Cell 26, 237–249, August 12, 2013 ª2013 ElsevieBlood flow is required for HSC emergence in the DA (North et al.,
2009) but is unlikely to explain the failure to express hematopoi-
etic gene expression in the residual DA as failure to activate
expression of gata2 and runx1 at stages 34 and 36, respectively,
precedes the time that circulation normally commences in the
embryos at stage 38 (Figures 5D and S1B).
In conclusion, the disruption of hemangioblast specification in
the DLP in the miR-142-3p and dgcr8morphants results in a fail-
ure to form an intact DA that precludes the emergence of hemo-
genic endothelial cells and ultimately HSCs.
miR-142-3p Targets TGFb Family Receptors in Order to
Promote Hemangioblast Specification of Lateral Plate
Mesoderm
We established that miR-142-3p is required to activate a
cascade of TFs and signaling molecules in the DLP to promote
definitive hemangioblast specification but miRNAs are generally
negative genetic regulators. We therefore hypothesized that
miR-142-3p must downregulate an inhibitor of the hemangio-
blast fate, forming a double-negative gate that controls entry
into the hematoendothelial program. Using Targetscan (http://
www.targetscan.org; Lewis et al., 2005), we identified three
members of the TGFb receptor superfamily, tgfbr1, acvr2a,
and acvr1b, as predicted targets of miR-142-3p in Xenopus
(Figure 6A). Both tgfbr1 and acvr2a are conserved targets of
miR-142-3p in mammals, as determined by all four major target
prediction programs (Targetscan, Pictar, PITA, andMiranda) and
have been validated by crosslinking and immunoprecipitation
(CLIP) analyses, suggesting that miR-142-3p has a highly
conserved role in regulating TGFb family signaling (Chi et al.,
2009; Gottwein et al., 2011; Yang et al., 2011). Furthermore,
miR-142-3p has been linked with various components of the
TGFb signaling pathway, including tgfbr1, in a variety of settings
(Carlsen et al., 2013; Danger et al., 2012; Kim et al., 2011; Lei
et al., 2012; Wang et al., 2012b).
Many studies have suggested that TGFb signaling has an
inhibitory effect on blood development in vitro (Park et al.,
2004; Poon et al., 2006; Sato et al., 2008; Wang et al., 2012a;
Zhang et al., 2011), and therefore we asked whether miR-142-
3p inhibits TGFb signaling to promote the specification of defin-
itive hemangioblasts. In situ hybridization analysis showed that
the expression of the predicted miR-142-3p target, tgfbr1, is
upregulated in the DLP region in miR-142-3p morphants
(Figure 6B). Therefore, we hypothesized that elevated TGFb
signaling in the DLP of miR-142-3p morphants is responsible
for the failure to initiate the hemangioblast program, and it may
therefore be possible to rescue the effect of the MO by inhibiting
TGFb signaling (summarized in Figure 6C). To investigate this,
we used both a pan-TGFb/Activin/Nodal receptor type I inhibitor,
SB431542 (Inman et al., 2002), and a specific Tgfbr1 inhibitor,
LY2157299 (Bueno et al., 2008). Consistent with our hypothesis,
both SB431542 and LY2157299 treatment from stages 16–17,
prior to the start of the hemangioblast program in the DLP at
stage 20, partially rescued flk1 expression in the DLP of miR-
142-3p morphants (Figure 6D). Therefore, our data suggest
that miR-142-3p participates in a double-negative gate unlock-
ing definitive hemangioblast programming in part by restricting
inhibitory TGFb signaling in lateral plate mesoderm (summarized
in Figure 6E).r Inc.
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Figure 5. Vasculogenesis Defects in miR-142-3p Morphants
(A)Hemogenicendothelium isnot formed inmiR-142-3pmorphants. Insituhybridizationanalysis ofgfi1aandspibexpression in themidline (arrowheads)at stage39.
(B) Endothelial differentiation and migration defects in miR-142-3p morphants. WISH analysis of flt4, flk1, and flt1 expression in DLP-derived angioblasts in the
PCV (arrows) and in cells migrating to the midline to form the DA (arrowheads) at stage 30.
(C) Defective expression of endothelial markers in miR-142-3p morphants. WISH analysis of AA4.1,CD31, dll4, and cx37 in the DA (arrowhead) and PCV (arrows)
at stage 34.
(D) A residual DA is formed inmiR-142-3pmorphants (as shown byWISH analysis ofCD31, arrowhead) but fails to switch on the hematopoietic TFs gata2 at stage
34 or runx1 at stage 36, as shown by WISH. Position of the DA is indicated by arrowheads.
The number of embryos represented by each panel, out of the number analyzed, is indicated in the top right corner. The anterior of the embryo is to the left and
dorsal to the top in all images.
See also Figure S4.
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We have identified an essential role for miRNA regulation in the
gene regulatory network, controlling the specification of the
hemangioblast precursors of the blood stem cell lineage from
lateral plate mesoderm by knocking down the miRNA process-
ing factor, Dgcr8. Using a morpholino to inhibit miR-142-3p,
we demonstrated that this miRNA is required to initiate the
specification of the definitive hemangioblasts. miR-142-3p
morphants phenocopy closely the hematoendothelial defects
in dgcr8 morphants, and crucially, miR-142-3p is sufficient to
rescue hemangioblast formation in Dgcr8-depleted embryos,
suggesting that this is the primary miRNA governing the initialDevelopspecification of the definitive hemangioblasts in lateral plate
mesoderm. We have shown that miR-142-3p is the earliest
known regulator of the hematoendothelial lineage, acting
upstream of the hematopoietic TFs Fli1, Gata2, Etv2, and Scl,
at the top of the hierarchy, specifying HSC and endothelial
programming in the DLP and thereby tabling this miRNA as a
master regulator of definitive hemangioblast specification. Our
analysis of miR-142-3p has suggested the presence of a
double-negative gate at the nexus of the GRN, controlling
definitive hemangioblast specification, in which a repressor,
miR-142-3p, activates the hematoendothelial program through
downregulation of inhibitory factors, at least in part via modu-
lation of TGFb signaling. The double-negative gate may be amental Cell 26, 237–249, August 12, 2013 ª2013 Elsevier Inc. 245
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Figure 6. miR-142-3p Restricts Inhibitory TGFb Signaling and Forms a Double-Negative Gate, Thereby Controlling the Initiation of the
Hemangioblast Program
(A) Alignments of the target sites in tgfbr1, acvr2a, and acvr1b (blue) with miR-142-3p miRNA (red).
(B) WISH analysis at stages 25–26 showing that tgfbr1 expression is elevated in the DLP region (arrows) in miR-142-3p morphants.
(C) Schematic diagram summarizing the rescue experiments performed with the TGFb type I receptor kinase inhibitors, SB431542 and LY2157299, in miR-
142-3p morphants.
(legend continued on next page)
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miR-142 Controls Hemangioblast Specificationgeneral mechanism by which cell fates are unlocked during
embryonic development (Davidson and Levine, 2008; Oliveri
et al., 2008), and as obligate repressors, miRNAs are potentially
important components of such motifs. These findings challenge
the view that individual miRNAs simply fine-tune GRNs in which
TFs are the major players (Hornstein and Shomron, 2006). Our
data demonstrate that miR-142-3p is essential for the specifica-
tion of the hemangioblastic precursors of the blood stem cell
lineage and suggests that miRNAs can be instructive determi-
nants of cell fate, as has been proposed for transcription factors
(Graf and Enver, 2009).
miR-142-3p has been reported to have various roles in hema-
topoiesis and leukemia; however, we have discovered that it
has an unanticipated function in the specification of the early
hematoendothelial precursors of the blood stem cell lineage.
Many of the TFs regulating HSC development in the embryo
have evolved to have additional important roles in adult hemato-
poietic cells and are often mutated or dysregulated in leukemia.
miR-142 was identified at the breakpoint of a translocation
involving the MYC oncogene in an aggressive B cell leukemia
(Gauwerky et al., 1989) and has recently been found to be
mutated in 20% of diffuse large B cell lymphomas (Kwanhian
et al., 2012). It will therefore be exciting to investigate whether
epigenetic or genomic alterations in this miRNA are involved in
driving hematological malignancies.
The identification of miR-142-3p as a master regulator of
definitive hemangioblast specification suggests that miR-142-
3p may facilitate HSC formation by enhancing the formation of
hemangioblast precursors during in vitro hematopoietic differen-
tiation of pluripotent stem cells. Furthermore, we have identified
other candidate miRNAs that may regulate HSC programming
through our analysis of miRNA expression in embryonic HSC
precursors. It may therefore be possible to identify a set of
miRNAs, including miR-142-3p, that are able to synergize with
cell signaling pathways to drive HSC emergence from pluripo-
tent stem cells for regenerative medicine, just as the miR-302/
367 cluster efficiently reprograms somatic cells to a pluripotent
state (Anokye-Danso et al., 2011).
EXPERIMENTAL PROCEDURES
Embryo Manipulation and Whole-Mount In Situ Hybridization
Embryos were obtained and cultured as described previously (Walmsley et al.,
2005) and staged in accordance with the method outlined in Nieuwkoop and
Faber (1967). Embryo microinjection and whole-mount in situ hybridization
(WISH) were performed as previously described (Walmsley et al., 2005). Before
photography, embryos were cleared in benzyl benzoate:benzyl alcohol (2:1).
For details of probes used, see Table S1. All embryoswere hybridized aswhole
mounts. All animal work was carried out according to UK Home Office regula-
tions under the appropriate project license.
Morpholinos and miR-142-3p Mimic
Morpholinos (MOs) (GeneTools) and miR-142-3p mimic (Dharmacon, Thermo
Fisher) were injected into both blastomeres of two-cell-stage Xenopus laevis
embryos in the following amounts per embryo: Dgcr8 MO, 10–15 ng; miR-(D) Treatment of miR-142-3p morphants with a pan-TGFb type I receptor family in
row), from stages 16–17 partially rescues the specification of hemangioblasts as
The number of embryos represented by each panel, out of the number analyzed
(E) Circuit diagram representing the DLP hemangioblast GRN based on data prese
Walmsley et al., 2002). Dashed connector indicates that the mechanism by whic
Develop142-3p MO and control mismatch MO, 100 ng; miR-142-5p MO, 40 ng; miR-
142-3pmimic, 10–12.5 fmol. MO sequences can be found in the Supplemental
Experimental Procedures.
Preparation and FACS Sorting of Mouse Cells
For purification of the adult mouseHSCpopulation, lineage negative cells were
isolated from bone marrow of C57BL/6, 9-week-old mice as described
previously (Rodrigues et al., 2005). Lineage depletion was performed using
AutoMACS and goat anti-rat IgGMicroBeads (Miltenyi). We used the following
lineage antibodies: purified rat anti-mouse CD45/B220, Gr-1, Mac1, CD3,
CD4, CD8 (eBioscience), and Ter119 (BioLegend). We used the following
antibodies for sorting HSCs: Sca1-PE (BD Pharmingen), c-Kit/CD117-APC,
CD135/Flt3-biotinylated, and Streptavidin-PE-Cy7 (eBioscience). F(ab’)2
fragment of goat anti-rat IgG (H+L)-PE-Cy5 (Molecular Probes) secondary anti-
body was used to exclude Lin+ cells. Hoechst58 was used to exclude dead
cells. Cell sorting was performed on a MoFlo (Beckman Coulter), and cells
were collected in RNA later.
For isolation of mouse AGM populations (as described previously in Ruiz-
Herguido et al., 2012), CD1 embryos were obtained at 11 days after detection
of vaginal plug. The AGM region was dissected and digested in 0.1% collage-
nase (Sigma-Aldrich) in PBS supplemented with 10% FBS for 20 min at 37C.
Cells were stained for 30 min with the different antibodies. We used the
following antibodies from Becton Dickinson : CD31-PE, CD45-PECy7, and
CD117-APC. Ter119-FITC (BD) was used to exclude erythroid cells, and
DAPI staining (Molecular Probes) was used to exclude dead cells. Cell sorting
was performed on a FACS Aria (BD), and cells were collected in RNAlater
solution.
miRNA Profiling and qRT-PCR
Megaplex primer pools were used to perform reverse transcription and pream-
plification of mouse RNA samples, and miRNA profiling was performed using
Taqman Rodent miRNA Arrays (v2.0) on a 7900HT quantitative real-time PCR
machine (Applied Biosystems). Individual TaqmanmiRNA assayswere used to
quantify relative expression of miR-142-3p and miR-142-5p in mouse and
Xenopus RNA samples normalized to the endogenous control, U6 small
nuclear RNA.
Bioinformatic and Statistical Analysis
miRNAs undetectable in all of the AGM populations analyzed were removed
from the analysis, and mean DCt values were calculated for each remaining
miRNA. Genesis software was used to perform clustering analysis. DCt values
were mean centered and normalized by SD to calculate the Z score, and
hierarchical clustering was performed using Pearson’s correlation.
ChIP-seq peak data for ten hematopoietic TFs in mouse hematopoietic
progenitors was obtained from a published data set (Wilson et al., 2010).
The number of peaks was scored for each TF within ±5 kb of the mouse
pre-miRNA loci obtained from miRBase (http://www.mirbase.org; Kozomara
and Griffiths-Jones, 2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2013.06.023.
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